PMID- 28222461
OWN - NLM
STAT- MEDLINE
DCOM- 20170605
LR  - 20181203
IS  - 1533-7294 (Electronic)
IS  - 0094-3509 (Linking)
VI  - 66
IP  - 2 Suppl
DP  - 2017 Feb
TI  - Elements for Success in Managing Type 2 Diabetes With SGLT-2 Inhibitors: 
      Individualizing Treatment With SGLT-2 Inhibitor Therapy in Type 2 Diabetes 
      Mellitus.
PG  - S13-S16
AB  - The largely self-managed nature of type 2 diabetes mellitus (T2DM) underscores 
      the importance of a collaborative decision-making process between patient and 
      provider that best aligns the medication characteristics with the needs, 
      interests, and abilities of the patient and with the treatment goals. The 
      treatment regimen should be kept as simple as possible. This article applies 
      these general principles to the use of sodium glucose cotransporter-2 inhibitor 
      (SGLT-2) therapy, based on evidence from published studies and the clinical 
      experience of the author.
FAU - Miller, Eden M
AU  - Miller EM
AD  - Executive Director and Co-founder, Diabetes Nation, High Lakes Health Care, St. 
      Charles Hospital, Bend, OR, USA.
LA  - eng
PT  - Case Reports
PT  - Journal Article
PL  - United States
TA  - J Fam Pract
JT  - The Journal of family practice
JID - 7502590
RN  - 0 (Blood Glucose)
RN  - 0 (Hypoglycemic Agents)
RN  - 0 (Sodium-Glucose Transporter 2)
RN  - 0 (Sodium-Glucose Transporter 2 Inhibitors)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Blood Glucose/*drug effects
MH  - Diabetes Mellitus, Type 2/*drug therapy
MH  - Female
MH  - Humans
MH  - Hypoglycemic Agents/*therapeutic use
MH  - Male
MH  - Middle Aged
MH  - *Precision Medicine
MH  - Sodium-Glucose Transporter 2/*therapeutic use
MH  - *Sodium-Glucose Transporter 2 Inhibitors
MH  - United States
EDAT- 2017/02/22 06:00
MHDA- 2017/06/06 06:00
CRDT- 2017/02/22 06:00
PHST- 2017/02/22 06:00 [entrez]
PHST- 2017/02/22 06:00 [pubmed]
PHST- 2017/06/06 06:00 [medline]
AID - jfp_6602l [pii]
PST - ppublish
SO  - J Fam Pract. 2017 Feb;66(2 Suppl):S13-S16.